glycine has been researched along with Diabetes Mellitus, Adult-Onset in 126 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results implicate a key role for renin and endothelin-1 in the edema caused by PPARgamma agonists and demonstrate how knowledge gained from pharmacogenetic studies can be applied in drug discovery." | 9.13 | Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. ( Achanzar, W; Cheng, P; Cosma, G; Delmonte, T; Dracopoli, NC; Geese, WJ; Hariharan, N; Hui, L; Krishnan, B; Ordway, N; Ranade, K; Rubin, C; Tomlinson, L, 2008) |
| "Plasma glycine level is low in patients with obesity or diabetes and the improvement of insulin resistance increases plasma glycine concentration." | 8.98 | Insulin resistance and glycine metabolism in humans. ( Adeva-Andany, M; Ameneiros-Rodríguez, E; Domínguez-Montero, A; Donapetry-García, C; Fernández-Fernández, C; Souto-Adeva, G, 2018) |
| "Obesity is associated with altered glycine metabolism in humans." | 7.96 | Obesity increases hepatic glycine dehydrogenase and aminomethyltransferase expression while dietary glycine supplementation reduces white adipose tissue in Zucker diabetic fatty rats. ( Edwards, AK; McKnight, SM; Satterfield, MC; Simmons, RM; Wu, G, 2020) |
| "Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPARalpha/gamma agonist that is in advanced clinical development for the treatment of type 2 diabetes and its associated dyslipidemia." | 6.43 | Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. ( Cox, SL, 2005) |
| "To investigate the causal role of choline metabolites mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in coronary artery disease (CAD) and type 2 diabetes (T2D) using Mendelian randomization (MR)." | 5.22 | SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. ( Bi, Y; Hou, T; Li, M; Lin, H; Lu, J; Ning, G; Wang, S; Wang, T; Wang, W; Xu, M; Xu, Y; Zhao, Z; Zheng, J, 2022) |
| "The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood." | 5.20 | The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. ( Cersosimo, E; Coletta, DK; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N, 2015) |
| "Muraglitazar (i) improves glycaemic control by enhancing insulin sensitivity and β cell function in T2DM subjects, (ii) improves multiple cardiovascular risk factors, (iii) reduces muscle, visceral and hepatic fat content in T2DM subjects." | 5.15 | Metabolic effects of muraglitazar in type 2 diabetic subjects. ( Casolaro, A; Cersosimo, E; DeFronzo, RA; Fernandez, M; Ferrannini, E; Gastaldelli, A; Hardies, J; Musi, N; Petz, R; Tantiwong, P; Triplitt, C, 2011) |
| "Our results implicate a key role for renin and endothelin-1 in the edema caused by PPARgamma agonists and demonstrate how knowledge gained from pharmacogenetic studies can be applied in drug discovery." | 5.13 | Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. ( Achanzar, W; Cheng, P; Cosma, G; Delmonte, T; Dracopoli, NC; Geese, WJ; Hariharan, N; Hui, L; Krishnan, B; Ordway, N; Ranade, K; Rubin, C; Tomlinson, L, 2008) |
| "Circulating levels of glycine have previously been associated with lower incidence of coronary heart disease (CHD) and type 2 diabetes (T2D) but it remains uncertain if glycine plays an aetiological role." | 5.01 | Assessing the causal association of glycine with risk of cardio-metabolic diseases. ( Burgess, S; Butterworth, AS; Danesh, J; Day, FR; Erdmann, J; Forouhi, NG; Griffin, JL; Howson, JMM; Imamura, F; Karthikeyan, S; Khaw, KT; Koulman, A; Langenberg, C; Lotta, LA; Oliver-Williams, C; Schunkert, H; Scott, RA; Stewart, ID; Surendran, P; Wareham, NJ; Wittemans, LBL; Wood, AM; Zeng, L, 2019) |
| "Plasma glycine level is low in patients with obesity or diabetes and the improvement of insulin resistance increases plasma glycine concentration." | 4.98 | Insulin resistance and glycine metabolism in humans. ( Adeva-Andany, M; Ameneiros-Rodríguez, E; Domínguez-Montero, A; Donapetry-García, C; Fernández-Fernández, C; Souto-Adeva, G, 2018) |
| "Obesity is associated with altered glycine metabolism in humans." | 3.96 | Obesity increases hepatic glycine dehydrogenase and aminomethyltransferase expression while dietary glycine supplementation reduces white adipose tissue in Zucker diabetic fatty rats. ( Edwards, AK; McKnight, SM; Satterfield, MC; Simmons, RM; Wu, G, 2020) |
| "Muraglitazar is a dual (alpha/gamma) PPAR activator." | 2.74 | Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. ( Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K, 2009) |
| "Treatment with glycine is likely to have a beneficial effect on innate and adaptive immune responses and may help prevent tissue damage caused by chronic inflammation in patients with Type 2 diabetes." | 2.73 | Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. ( Carvajal-Sandoval, G; Cruz, M; Kumate, J; Maldonado-Bernal, C; Mondragón-Gonzalez, R; Sanchez-Barrera, R; Wacher, NH, 2008) |
| "Muraglitazar was generally well tolerated." | 2.71 | Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. ( Buse, JB; Davidson, JA; Frederich, R; Lin, KC; Montoro, R; Rubin, CJ; Shockey, G; Viraswami-Appanna, K, 2005) |
| "The onset and/or progression of type 2 diabetes (T2D) can be prevented if intervention is early enough." | 2.55 | Impaired "Glycine"-mia in Type 2 Diabetes and Potential Mechanisms Contributing to Glucose Homeostasis. ( MacDonald, PE; Yan-Do, R, 2017) |
| "Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control." | 2.50 | Systematic reviews to ascertain the safety of diabetes medications. ( Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH, 2014) |
| "Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPARalpha/gamma agonist that is in advanced clinical development for the treatment of type 2 diabetes and its associated dyslipidemia." | 2.43 | Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. ( Cox, SL, 2005) |
| "Gly482Ser was genotyped in a type 2 diabetes case-control study (N=1,096) using MassArray technology." | 2.43 | Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. ( Barroso, I; Crowley, V; Franks, PW; Luan, J; O'Rahilly, S; Sandhu, MS; Schafer, AJ; Wareham, NJ, 2006) |
| "Type 2 diabetes is recognised as a major cardiovascular risk factor, and future therapies must therefore address more than just blood glucose levels." | 2.43 | Diabetes: assessing the pipeline. ( Lebovitz, H, 2006) |
| " However, its absorption rate or plasma levels are impaired in bacterial infection or high glucose levels." | 1.56 | An association between glycine and insulin levels is observed in patients with pulmonary tuberculosis and type 2 diabetes. ( Alvarado-Vasquez, N; Bernal-Alcántara, D; Castillejos-López, M; Cerón, E; Juárez-Cruz, E; López-Bello, G; Moreno, J; Sommer, B; Zenil-Vega, M, 2020) |
| " Moreover, chronic administration of JTT-551 showed an antiobesity effect and an improvement of glucose and lipid metabolism in DIO mice." | 1.40 | Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. ( Fukuda, S; Ito, M; Morinaga, H; Ohta, T; Sakata, S, 2014) |
| "Metabolomic discovery of biomarkers of type 2 diabetes (T2D) risk may reveal etiological pathways and help to identify individuals at risk for disease." | 1.39 | Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. ( Adamski, J; Boeing, H; Drogan, D; Floegel, A; Fritsche, A; Häring, HU; Hrabě de Angelis, M; Illig, T; Joost, HG; Mühlenbruch, K; Peters, A; Pischon, T; Prehn, C; Roden, M; Schulze, MB; Stefan, N; Wang-Sattler, R; Yu, Z, 2013) |
| "A total of 130 patients with type 2 diabetes and 133 healthy subjects as control were randomly selected from January 2008 to January 2011 in endocrine wards of Zhengzhou People's Hospital." | 1.39 | Association of the G-250A promoter polymorphism in the hepatic lipase gene with the risk of type 2 diabetes mellitus. ( Fan, S; Guo, Y; Ou, L; Yao, L, 2013) |
| "Patients with uncontrolled type 2 diabetes have severely deficient synthesis of glutathione attributed to limited precursor availability." | 1.37 | Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. ( Balasubramanyam, A; Guthikonda, AP; Jahoor, F; McKay, SV; Patel, SG; Reddy, VT; Sekhar, RV, 2011) |
| "For the purpose, 195 subjects with type 2 diabetes with PDR were compared with 143 subjects with type 2 diabetes of duration of more than 10 years who had no clinical signs of diabetic retinopathy." | 1.35 | K469E polymorphism of the intracellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2 diabetes. ( Osredkar, J; Petrovic, D; Petrovic, MG; Saraga-Babić, M, 2008) |
| "Hyperglycaemia in Type 2 diabetes has a major role in the development of microvascular complications, whereas the dyslipidaemia is the major cause of macrovascular complications." | 1.33 | Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes? ( Doggrell, SA, 2006) |
| " We conclude that SNPs in PPARD modify the conversion from IGT to type 2 diabetes, particularly in combination with the SNPs of PGC-1A and PPARG2." | 1.33 | Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. ( Andrulionyte, L; Chiasson, JL; Laakso, M; Peltola, P, 2006) |
| "We analysed Japanese MODY patients for mutations in the HNF-1 alpha gene." | 1.31 | Identification of three new mutations of the HNF-1 alpha gene in Japanese MODY families. ( Ikema, T; Komiya, I; Shimabukuro, M; Shimajiri, Y; Sunakawa, S; Takasu, N; Tawata, M; Yogi, H, 2002) |
| " Finally, glucagon-stimulated insulin secretion by RIN cells expressing the mutant receptor was decreased such that the dose-response curve was shifted to the right in comparison to that obtained with cells expressing the wild type receptor." | 1.29 | The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. ( Abrahamsen, N; Froguel, P; Hager, J; Hansen, LH; Jelinek, L; Kindsvogel, W; Nishimura, E, 1996) |
| "None of the NIDDM or impaired glucose tolerant patients had this polymorphism." | 1.29 | Lack of association between the Gly40Ser polymorphism in the glucagon receptor gene and NIDDM in Finland. ( Groop, L; Huang, X; Lehto, M; Orho, M, 1995) |
| " In the healthy individuals, urinary guanidinoacetic acid excretion increased 5-fold by 2 h after dosing (15." | 1.28 | Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading. ( Kadono, K; Tetsutani, T; Yamaguchi, T; Yasunaga, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.79) | 18.7374 |
| 1990's | 22 (17.46) | 18.2507 |
| 2000's | 56 (44.44) | 29.6817 |
| 2010's | 31 (24.60) | 24.3611 |
| 2020's | 16 (12.70) | 2.80 |
| Authors | Studies |
|---|---|
| Semiz, S | 1 |
| Zou, H | 1 |
| Huang, C | 1 |
| Zhou, L | 1 |
| Lu, R | 1 |
| Zhang, Y | 1 |
| Lin, D | 1 |
| Wang, KX | 1 |
| Liang, FX | 1 |
| Wu, S | 1 |
| Chen, S | 3 |
| Luo, ZH | 1 |
| Han, YL | 1 |
| Chen, J | 2 |
| Chen, B | 1 |
| Chen, ZQ | 1 |
| Zhang, YL | 1 |
| Zhou, T | 1 |
| Gu, XL | 1 |
| Xu, M | 1 |
| Zheng, J | 1 |
| Hou, T | 1 |
| Lin, H | 1 |
| Wang, T | 1 |
| Wang, S | 2 |
| Lu, J | 1 |
| Zhao, Z | 1 |
| Li, M | 1 |
| Xu, Y | 1 |
| Ning, G | 1 |
| Bi, Y | 1 |
| Wang, W | 3 |
| Unnikrishnan, AC | 1 |
| Shanmugam, G | 1 |
| Canet, F | 2 |
| Christensen, JJ | 2 |
| Victor, VM | 2 |
| Hustad, KS | 2 |
| Ottestad, I | 2 |
| Rundblad, A | 2 |
| Sæther, T | 2 |
| Dalen, KT | 2 |
| Ulven, SM | 2 |
| Holven, KB | 2 |
| Telle-Hansen, VH | 2 |
| Holeček, M | 1 |
| Yun, JH | 1 |
| Lee, HS | 1 |
| Yu, HY | 1 |
| Kim, YJ | 1 |
| Jeon, HJ | 1 |
| Oh, T | 1 |
| Kim, BJ | 1 |
| Choi, HJ | 1 |
| Kim, JM | 1 |
| Sharma, A | 1 |
| Pagidipati, NJ | 1 |
| Califf, RM | 1 |
| McGuire, DK | 1 |
| Green, JB | 1 |
| Demets, D | 1 |
| George, JT | 1 |
| Gerstein, HC | 1 |
| Hobbs, T | 1 |
| Holman, RR | 1 |
| Lawson, FC | 1 |
| Leiter, LA | 1 |
| Pfeffer, MA | 1 |
| Reusch, J | 1 |
| Riesmeyer, JS | 1 |
| Roe, MT | 1 |
| Rosenberg, Y | 1 |
| Temple, R | 1 |
| Wiviott, S | 1 |
| McMurray, J | 1 |
| Granger, C | 1 |
| Zenil-Vega, M | 1 |
| Cerón, E | 1 |
| López-Bello, G | 1 |
| Moreno, J | 1 |
| Juárez-Cruz, E | 1 |
| Castillejos-López, M | 1 |
| Bernal-Alcántara, D | 1 |
| Sommer, B | 1 |
| Alvarado-Vasquez, N | 1 |
| Bonelli, R | 2 |
| Woods, SM | 1 |
| Ansell, BRE | 1 |
| Heeren, TFC | 1 |
| Egan, CA | 1 |
| Khan, KN | 1 |
| Guymer, R | 1 |
| Trombley, J | 1 |
| Friedlander, M | 1 |
| Bahlo, M | 2 |
| Fruttiger, M | 1 |
| Simmons, RM | 1 |
| McKnight, SM | 1 |
| Edwards, AK | 1 |
| Wu, G | 1 |
| Satterfield, MC | 1 |
| Kale, OE | 1 |
| Vongdip, M | 1 |
| Ogundare, TF | 1 |
| Osilesi, O | 1 |
| Kalliora, C | 1 |
| Drosatos, K | 1 |
| Jäger, S | 1 |
| Cuadrat, R | 1 |
| Wittenbecher, C | 1 |
| Floegel, A | 2 |
| Hoffmann, P | 1 |
| Prehn, C | 2 |
| Adamski, J | 2 |
| Pischon, T | 2 |
| Schulze, MB | 2 |
| Lotta, LA | 2 |
| Pietzner, M | 1 |
| Stewart, ID | 2 |
| Wittemans, LBL | 2 |
| Li, C | 2 |
| Raffler, J | 1 |
| Biggs, EK | 1 |
| Oliver-Williams, C | 2 |
| Auyeung, VPW | 1 |
| Luan, J | 2 |
| Wheeler, E | 1 |
| Paige, E | 1 |
| Surendran, P | 2 |
| Michelotti, GA | 1 |
| Scott, RA | 2 |
| Burgess, S | 2 |
| Zuber, V | 1 |
| Sanderson, E | 1 |
| Koulman, A | 2 |
| Imamura, F | 2 |
| Forouhi, NG | 2 |
| Khaw, KT | 2 |
| Griffin, JL | 2 |
| Wood, AM | 2 |
| Kastenmüller, G | 1 |
| Danesh, J | 2 |
| Butterworth, AS | 2 |
| Gribble, FM | 1 |
| Reimann, F | 1 |
| Fauman, E | 1 |
| Wareham, NJ | 3 |
| Langenberg, C | 2 |
| Jog, R | 1 |
| Chen, G | 2 |
| Wang, J | 1 |
| Leff, T | 1 |
| Yan-Do, R | 2 |
| MacDonald, PE | 2 |
| Adeva-Andany, M | 1 |
| Souto-Adeva, G | 1 |
| Ameneiros-Rodríguez, E | 1 |
| Fernández-Fernández, C | 1 |
| Donapetry-García, C | 1 |
| Domínguez-Montero, A | 1 |
| Vandenbeek, R | 1 |
| Khan, NP | 1 |
| Estall, JL | 1 |
| Merino, J | 1 |
| Leong, A | 1 |
| Liu, CT | 1 |
| Porneala, B | 1 |
| Walford, GA | 1 |
| von Grotthuss, M | 1 |
| Wang, TJ | 1 |
| Flannick, J | 1 |
| Dupuis, J | 1 |
| Levy, D | 1 |
| Gerszten, RE | 1 |
| Florez, JC | 1 |
| Meigs, JB | 1 |
| Karthikeyan, S | 1 |
| Day, FR | 1 |
| Zeng, L | 1 |
| Erdmann, J | 1 |
| Schunkert, H | 1 |
| Howson, JMM | 1 |
| Alves, A | 1 |
| Bassot, A | 1 |
| Bulteau, AL | 1 |
| Pirola, L | 1 |
| Morio, B | 1 |
| Cao, D | 1 |
| Ouyang, S | 1 |
| Liu, Z | 1 |
| Ma, F | 1 |
| Wu, J | 1 |
| Gionfriddo, MR | 1 |
| Morey-Vargas, OL | 1 |
| Brito, JP | 1 |
| Leppin, AL | 1 |
| Murad, MH | 1 |
| Montori, VM | 1 |
| Ito, M | 2 |
| Fukuda, S | 2 |
| Sakata, S | 2 |
| Morinaga, H | 2 |
| Ohta, T | 2 |
| Arshad, F | 1 |
| Laway, BA | 1 |
| Rather, TA | 1 |
| Kuchay, MS | 1 |
| Khan, SH | 1 |
| Coletta, DK | 1 |
| Fernandez, M | 2 |
| Cersosimo, E | 2 |
| Gastaldelli, A | 2 |
| Musi, N | 2 |
| DeFronzo, RA | 3 |
| Stec, DF | 1 |
| Stothers, C | 1 |
| Avance, J | 1 |
| Denson, D | 1 |
| Harris, R | 1 |
| Voziyan, P | 1 |
| Yin, YW | 1 |
| Wang, Q | 1 |
| Sun, QQ | 1 |
| Hu, AM | 1 |
| Liu, HL | 1 |
| Shibata, Y | 1 |
| Kagechika, K | 1 |
| Ota, M | 1 |
| Yamaguchi, M | 1 |
| Setoguchi, M | 1 |
| Kubo, H | 1 |
| Chiba, K | 1 |
| Takano, H | 1 |
| Akiyama, C | 1 |
| Ono, M | 1 |
| Nishi, M | 2 |
| Usui, H | 1 |
| Alsalman, HA | 1 |
| Kaabi, YA | 1 |
| Duong, E | 1 |
| Manning Fox, JE | 1 |
| Dai, X | 1 |
| Suzuki, K | 2 |
| Khan, S | 1 |
| Bautista, A | 1 |
| Ferdaoussi, M | 1 |
| Lyon, J | 1 |
| Wu, X | 1 |
| Cheley, S | 1 |
| Braun, M | 1 |
| Pérez-Torres, I | 1 |
| Zuniga-Munoz, AM | 1 |
| Guarner-Lans, V | 1 |
| Okauchi, Y | 1 |
| Iwahashi, H | 1 |
| Okita, K | 1 |
| Yuan, M | 1 |
| Matsuda, M | 1 |
| Tanaka, T | 1 |
| Miyagawa, J | 1 |
| Funahashi, T | 1 |
| Horikawa, Y | 1 |
| Shimomura, I | 1 |
| Yamagata, K | 2 |
| Rubin, CJ | 5 |
| Ledeine, JM | 2 |
| Fiedorek, FT | 4 |
| Geese, WJ | 1 |
| Achanzar, W | 1 |
| Rubin, C | 1 |
| Hariharan, N | 3 |
| Cheng, P | 1 |
| Tomlinson, L | 1 |
| Ordway, N | 1 |
| Dracopoli, NC | 1 |
| Delmonte, T | 1 |
| Hui, L | 1 |
| Krishnan, B | 1 |
| Cosma, G | 1 |
| Ranade, K | 1 |
| Cruz, M | 1 |
| Maldonado-Bernal, C | 1 |
| Mondragón-Gonzalez, R | 1 |
| Sanchez-Barrera, R | 1 |
| Wacher, NH | 1 |
| Carvajal-Sandoval, G | 1 |
| Kumate, J | 1 |
| Petrovic, MG | 1 |
| Osredkar, J | 1 |
| Saraga-Babić, M | 1 |
| Petrovic, D | 2 |
| Sparks, SM | 2 |
| Banker, P | 2 |
| Bickett, DM | 2 |
| Carter, HL | 1 |
| Clancy, DC | 2 |
| Dickerson, SH | 2 |
| Dwornik, KA | 1 |
| Garrido, DM | 2 |
| Golden, PL | 2 |
| Nolte, RT | 1 |
| Peat, AJ | 2 |
| Sheckler, LR | 2 |
| Tavares, FX | 2 |
| Thomson, SA | 2 |
| Wang, L | 2 |
| Weiel, JE | 2 |
| Ouederni, TB | 1 |
| Sanchez-Corona, J | 1 |
| Flores Martinez, SE | 1 |
| Ben Maiz, H | 1 |
| Skhiri, HA | 1 |
| Abid, HK | 1 |
| Benammar-Elgaaied, A | 1 |
| Charbonnel, B | 1 |
| Zhang, HM | 1 |
| Chen, LL | 1 |
| Liao, YF | 1 |
| Wu, ZH | 1 |
| Ye, F | 1 |
| Xu, S | 1 |
| Yi, LL | 1 |
| Burguete-Garcia, AI | 1 |
| Cruz-Lopez, M | 1 |
| Madrid-Marina, V | 1 |
| Lopez-Ridaura, R | 1 |
| Hernández-Avila, M | 1 |
| Cortina, B | 1 |
| Gómez, RE | 1 |
| Velasco-Mondragón, E | 1 |
| De Pril, V | 1 |
| Viraswami-Appanna, K | 2 |
| Nakagawa, Y | 2 |
| Tanaka, M | 1 |
| Matsushita, M | 1 |
| Sekhar, RV | 1 |
| McKay, SV | 1 |
| Patel, SG | 1 |
| Guthikonda, AP | 1 |
| Reddy, VT | 1 |
| Balasubramanyam, A | 1 |
| Jahoor, F | 1 |
| Muñoz-Carlin, Mde L | 1 |
| Rodríguez-Moctezuma, JR | 1 |
| Gómez Latorre, JG | 1 |
| Montes-Castillo, ML | 1 |
| Juárez-Adauta, S | 1 |
| Triplitt, C | 1 |
| Hardies, J | 1 |
| Casolaro, A | 1 |
| Petz, R | 1 |
| Tantiwong, P | 1 |
| Ferrannini, E | 2 |
| Yue, JT | 1 |
| Mighiu, PI | 1 |
| Naples, M | 1 |
| Adeli, K | 1 |
| Lam, TK | 1 |
| Pruimboom-Brees, IM | 1 |
| Francone, O | 1 |
| Pettersen, JC | 1 |
| Kerlin, RL | 1 |
| Will, Y | 1 |
| Amacher, DE | 1 |
| Boucher, GG | 1 |
| Morton, D | 1 |
| Mencarelli, M | 1 |
| Zulian, A | 1 |
| Cancello, R | 1 |
| Alberti, L | 1 |
| Gilardini, L | 1 |
| Di Blasio, AM | 1 |
| Invitti, C | 1 |
| Stefan, N | 2 |
| Yu, Z | 1 |
| Mühlenbruch, K | 1 |
| Drogan, D | 1 |
| Joost, HG | 1 |
| Fritsche, A | 1 |
| Häring, HU | 2 |
| Hrabě de Angelis, M | 1 |
| Peters, A | 1 |
| Roden, M | 1 |
| Wang-Sattler, R | 1 |
| Illig, T | 1 |
| Boeing, H | 1 |
| Liu, C | 1 |
| Nissim, I | 2 |
| Chen, P | 1 |
| Doliba, N | 1 |
| Zhang, T | 1 |
| Daikhin, Y | 1 |
| Stokes, D | 1 |
| Yudkoff, M | 1 |
| Bennett, MJ | 1 |
| Stanley, CA | 1 |
| Matschinsky, FM | 1 |
| Naji, A | 1 |
| Ou, L | 1 |
| Yao, L | 1 |
| Guo, Y | 1 |
| Fan, S | 1 |
| Narne, P | 1 |
| Ponnaluri, KC | 1 |
| Singh, S | 1 |
| Siraj, M | 1 |
| Ishaq, M | 1 |
| Xie, W | 1 |
| Wood, AR | 1 |
| Lyssenko, V | 1 |
| Weedon, MN | 1 |
| Knowles, JW | 1 |
| Alkayyali, S | 1 |
| Assimes, TL | 1 |
| Quertermous, T | 1 |
| Abbasi, F | 1 |
| Paananen, J | 1 |
| Häring, H | 1 |
| Hansen, T | 1 |
| Pedersen, O | 4 |
| Smith, U | 1 |
| Laakso, M | 3 |
| Dekker, JM | 1 |
| Nolan, JJ | 1 |
| Groop, L | 3 |
| Adam, KP | 1 |
| Gall, WE | 1 |
| Frayling, TM | 1 |
| Walker, M | 1 |
| Ikema, T | 1 |
| Shimajiri, Y | 2 |
| Komiya, I | 1 |
| Tawata, M | 1 |
| Sunakawa, S | 1 |
| Yogi, H | 1 |
| Shimabukuro, M | 1 |
| Takasu, N | 1 |
| D'Alfonso, R | 1 |
| Marini, MA | 2 |
| Frittitta, L | 1 |
| Sorge, R | 1 |
| Frontoni, S | 2 |
| Porzio, O | 1 |
| Mariani, LM | 1 |
| Lauro, D | 2 |
| Gambardella, S | 1 |
| Trischitta, V | 1 |
| Federici, M | 2 |
| Lauro, R | 2 |
| Sesti, G | 2 |
| Muller, YL | 1 |
| Bogardus, C | 2 |
| Baier, L | 1 |
| Kimura, F | 1 |
| Hasegawa, G | 1 |
| Obayashi, H | 1 |
| Adachi, T | 1 |
| Hara, H | 1 |
| Ohta, M | 1 |
| Fukui, M | 1 |
| Kitagawa, Y | 1 |
| Park, H | 1 |
| Nakamura, N | 1 |
| Nakano, K | 1 |
| Yoshikawa, T | 1 |
| Cho, YM | 1 |
| Kim, M | 1 |
| Park, KS | 1 |
| Kim, SY | 1 |
| Lee, HK | 1 |
| Kovacs, P | 1 |
| Stumvoll, M | 1 |
| Hanson, RL | 1 |
| Lehn-Stefan, A | 1 |
| Permana, PA | 1 |
| Baier, LJ | 1 |
| Tataranni, PA | 1 |
| Silver, K | 1 |
| Jellema, A | 1 |
| Zeegers, MP | 1 |
| Feskens, EJ | 1 |
| Dagnelie, PC | 1 |
| Mensink, RP | 1 |
| Ikarashi, T | 1 |
| Hanyu, O | 1 |
| Maruyama, S | 1 |
| Souda, S | 1 |
| Kobayashi, C | 1 |
| Abe, E | 1 |
| Ukisu, J | 1 |
| Naganuma, K | 1 |
| Suzuki, A | 1 |
| Toya, M | 1 |
| Kaneko, S | 1 |
| Nakagawa, O | 1 |
| Aizawa, Y | 1 |
| Rudofsky, G | 1 |
| Reismann, P | 1 |
| Witte, S | 1 |
| Humpert, PM | 1 |
| Isermann, B | 1 |
| Chavakis, T | 1 |
| Tafel, J | 1 |
| Nosikov, VV | 1 |
| Hamann, A | 1 |
| Nawroth, P | 1 |
| Bierhaus, A | 1 |
| D'Adamo, M | 1 |
| Perego, L | 1 |
| Cardellini, M | 1 |
| Andreozzi, F | 1 |
| Sciacqua, A | 1 |
| Sbraccia, P | 1 |
| Paganelli, M | 1 |
| Pontiroli, AE | 1 |
| Perticone, F | 1 |
| Folli, F | 1 |
| Kunej, T | 1 |
| Globocnik Petrovic, M | 1 |
| Dovc, P | 1 |
| Peterlin, B | 1 |
| Devasthale, PV | 1 |
| Jeon, Y | 2 |
| Qu, F | 2 |
| Shao, C | 2 |
| Zhang, H | 2 |
| Cap, M | 3 |
| Farrelly, D | 2 |
| Golla, R | 1 |
| Grover, G | 1 |
| Harrity, T | 2 |
| Ma, Z | 1 |
| Moore, L | 1 |
| Ren, J | 2 |
| Seethala, R | 2 |
| Cheng, L | 1 |
| Sleph, P | 1 |
| Sun, W | 1 |
| Tieman, A | 2 |
| Wetterau, JR | 1 |
| Doweyko, A | 1 |
| Chandrasena, G | 1 |
| Chang, SY | 2 |
| Humphreys, WG | 1 |
| Sasseville, VG | 1 |
| Biller, SA | 2 |
| Ryono, DE | 1 |
| Selan, F | 1 |
| Cheng, PT | 2 |
| Sanke, T | 2 |
| Sakagashira, S | 2 |
| Nakagawa, T | 1 |
| Furuta, H | 1 |
| Shimomura, H | 1 |
| Hanabusa, T | 1 |
| Sasaki, H | 1 |
| Nanjo, K | 1 |
| Augeri, DJ | 1 |
| Robl, JA | 1 |
| Betebenner, DA | 1 |
| Magnin, DR | 1 |
| Khanna, A | 1 |
| Robertson, JG | 1 |
| Wang, A | 1 |
| Simpkins, LM | 1 |
| Taunk, P | 1 |
| Huang, Q | 1 |
| Han, SP | 1 |
| Abboa-Offei, B | 1 |
| Xin, L | 1 |
| Tao, L | 1 |
| Tozzo, E | 1 |
| Welzel, GE | 1 |
| Egan, DM | 1 |
| Marcinkeviciene, J | 1 |
| Kirby, MS | 1 |
| Parker, RA | 1 |
| Hamann, LG | 1 |
| Dilek, S | 1 |
| Ertunc, D | 1 |
| Tok, EC | 1 |
| Erdal, EM | 1 |
| Aktas, A | 1 |
| Buse, JB | 1 |
| Frederich, R | 1 |
| Lin, KC | 1 |
| Montoro, R | 1 |
| Shockey, G | 1 |
| Davidson, JA | 1 |
| Nissen, SE | 1 |
| Wolski, K | 1 |
| Topol, EJ | 1 |
| Brophy, JM | 1 |
| Kordella, T | 1 |
| Cox, SL | 1 |
| Chu, C | 1 |
| Kunselman, L | 1 |
| Gu, L | 1 |
| Ponticiello, R | 1 |
| Fenderson, W | 1 |
| Devasthale, P | 1 |
| Yang, WP | 1 |
| Zhou, M | 1 |
| Ryono, D | 1 |
| Biller, S | 1 |
| Mookhtiar, KA | 1 |
| Wetterau, J | 1 |
| Gregg, R | 1 |
| Barroso, I | 1 |
| Sandhu, MS | 1 |
| Franks, PW | 1 |
| Crowley, V | 1 |
| Schafer, AJ | 1 |
| O'Rahilly, S | 1 |
| Lebovitz, H | 1 |
| Heinzl, S | 1 |
| Liu, W | 1 |
| Liu, M | 1 |
| Fan, W | 1 |
| Nawata, H | 1 |
| Yanase, T | 1 |
| Liebson, PR | 1 |
| Kendall, DM | 1 |
| Mohideen, P | 1 |
| Belder, R | 1 |
| Gross, J | 1 |
| Norwood, P | 1 |
| O'Mahony, M | 1 |
| Sall, K | 1 |
| Sloan, G | 1 |
| Roberts, A | 1 |
| Parra, D | 1 |
| Beckey, C | 1 |
| Thomas, T | 1 |
| Najman, DM | 1 |
| Doggrell, SA | 1 |
| Andrulionyte, L | 1 |
| Peltola, P | 1 |
| Chiasson, JL | 1 |
| Fiévet, C | 1 |
| Fruchart, JC | 1 |
| Staels, B | 1 |
| Gao, JX | 1 |
| Xu, DL | 1 |
| Shao, YH | 1 |
| Lao, WY | 1 |
| Lin, S | 1 |
| Zhang, B | 1 |
| Gougeon, R | 2 |
| Morais, JA | 2 |
| Chevalier, S | 1 |
| Pereira, S | 1 |
| Lamarche, M | 1 |
| Marliss, EB | 2 |
| Chen, Y | 1 |
| Huang, H | 1 |
| Zhou, J | 1 |
| Doumatey, A | 1 |
| Lashley, K | 1 |
| Agyenim-Boateng, K | 1 |
| Eghan, BA | 1 |
| Acheampong, J | 1 |
| Fasanmade, O | 1 |
| Johnson, T | 1 |
| Akinsola, FB | 1 |
| Okafor, G | 1 |
| Oli, J | 1 |
| Ezepue, F | 1 |
| Amoah, A | 1 |
| Akafo, S | 1 |
| Adeyemo, A | 1 |
| Rotimi, CN | 1 |
| Fujisawa, T | 1 |
| Ikegami, H | 1 |
| Yamato, E | 1 |
| Takekawa, K | 1 |
| Hamada, Y | 1 |
| Ueda, H | 1 |
| Fukuda, M | 1 |
| Ogihara, T | 1 |
| Orho, M | 2 |
| Nikula-Ijäs, P | 1 |
| Schalin-Jäntti, C | 1 |
| Permutt, MA | 2 |
| Groop, LC | 1 |
| Page, RC | 1 |
| Hattersley, AT | 1 |
| Levy, JC | 1 |
| Barrow, B | 1 |
| Patel, P | 1 |
| Lo, D | 1 |
| Wainscoat, JS | 1 |
| Bell, GI | 1 |
| Turner, RC | 1 |
| Hitman, GA | 1 |
| Hawrami, K | 1 |
| McCarthy, MI | 1 |
| Viswanathan, M | 1 |
| Snehalatha, C | 1 |
| Ramachandran, A | 1 |
| Tuomilehto, J | 1 |
| Tuomilehto-Wolf, E | 1 |
| Nissinen, A | 1 |
| Shimokawa, K | 1 |
| Kadowaki, H | 1 |
| Sakura, H | 1 |
| Otabe, S | 1 |
| Hagura, R | 1 |
| Kosaka, K | 1 |
| Yazaki, Y | 1 |
| Akanuma, Y | 1 |
| Kadowaki, T | 1 |
| Hansen, LH | 1 |
| Abrahamsen, N | 1 |
| Hager, J | 1 |
| Jelinek, L | 1 |
| Kindsvogel, W | 1 |
| Froguel, P | 2 |
| Nishimura, E | 1 |
| Almind, K | 1 |
| Inoue, G | 1 |
| Kahn, CR | 1 |
| Cangialosi, G | 1 |
| Doria, G | 1 |
| Costa, R | 1 |
| Cirrincione, M | 1 |
| Salerno, V | 1 |
| Allegra, G | 1 |
| Scaffidi, A | 1 |
| Huang, X | 1 |
| Lehto, M | 1 |
| Hart, LM | 1 |
| Stolk, RP | 1 |
| Jansen, JJ | 1 |
| Grobbee, DE | 1 |
| Lemkes, HH | 1 |
| Maassen, JA | 1 |
| Esposito, DL | 1 |
| Mammarella, S | 1 |
| Ranieri, A | 1 |
| Della Loggia, F | 1 |
| Capani, F | 1 |
| Consoli, A | 1 |
| Mariani-Costantini, R | 1 |
| Caramia, FG | 1 |
| Cama, A | 1 |
| Battista, P | 1 |
| Chuang, LM | 1 |
| Lai, CS | 1 |
| Yeh, JI | 1 |
| Wu, HP | 1 |
| Tai, TY | 1 |
| Lin, BJ | 1 |
| Odawara, M | 2 |
| Matsunuma, A | 1 |
| Yamashita, K | 2 |
| Tachi, Y | 1 |
| Jones, PJ | 1 |
| Pencharz, PB | 1 |
| Bissé, E | 1 |
| Zorn, N | 1 |
| Eigel, A | 1 |
| Lizama, M | 1 |
| Huaman-Guillen, P | 1 |
| März, W | 1 |
| Van Dorsselaer, A | 1 |
| Wieland, H | 1 |
| Boutin, P | 1 |
| Gresh, L | 1 |
| Cisse, A | 1 |
| Hara, M | 1 |
| Bell, G | 1 |
| Babu, S | 1 |
| Eisenbarth, G | 1 |
| Liu, L | 1 |
| Xiang, K | 1 |
| Koch, M | 1 |
| Rett, K | 1 |
| Volk, A | 1 |
| Maerker, E | 1 |
| Haist, K | 1 |
| Deninger, M | 1 |
| Renn, W | 1 |
| Ambrosch, A | 1 |
| Lobmann, R | 1 |
| Dierkes, J | 1 |
| König, W | 1 |
| Luley, C | 1 |
| Lehnert, H | 1 |
| Carvajal Sandoval, G | 1 |
| Medina Santillán, R | 1 |
| Juárez, E | 1 |
| RamosMartínez, G | 1 |
| Carvajal Juárez, ME | 1 |
| Pulkkinen, A | 1 |
| Viitanen, L | 1 |
| Kareinen, A | 1 |
| Lehto, S | 1 |
| Hayakawa, T | 1 |
| Nagai, Y | 1 |
| Ando, H | 1 |
| Yamashita, H | 1 |
| Takamura, T | 1 |
| Abe, T | 1 |
| Nomura, G | 1 |
| Kobayashi, KI | 1 |
| Bengtsson, K | 1 |
| Orho-Melander, M | 1 |
| Melander, O | 1 |
| Lindblad, U | 1 |
| Ranstam, J | 1 |
| Råstam, L | 1 |
| González-Ortiz, M | 1 |
| Medina-Santillán, R | 1 |
| Martínez-Abundis, E | 1 |
| von Drateln, CR | 1 |
| Kadono, K | 1 |
| Yamaguchi, T | 1 |
| Tetsutani, T | 1 |
| Yasunaga, K | 1 |
| Gulliford, MC | 1 |
| Bicknell, EJ | 1 |
| Pover, GG | 1 |
| Scarpello, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters: A Clinical and Ex-vivo Study.[NCT03850314] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih T[NCT00095030] | Phase 3 | 1,752 participants | Interventional | 2004-02-29 | Completed | ||
| Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673] | 59 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants)) | |||
| A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therap[NCT00162175] | Phase 3 | 534 participants | Interventional | 2003-07-31 | Completed | ||
| A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes[NCT00240383] | Phase 2/Phase 3 | 1,260 participants | Interventional | 2002-05-31 | Completed | ||
| Effect of Insulin Resistance on Branched Chain Amino Acid Metabolism.[NCT04886973] | 40 participants (Actual) | Interventional | 2022-03-31 | Completed | |||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for glycine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.
Topics: Choline; Coronary Artery Disease; Diabetes Mellitus, Type 2; Genome-Wide Association Study; Glycine; | 2022 |
Role of Impaired Glycolysis in Perturbations of Amino Acid Metabolism in Diabetes Mellitus.
Topics: Amino Acids; Amino Acids, Branched-Chain; Diabetes Mellitus, Type 2; Glycine; Glycolysis; Humans; Py | 2023 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energ | 2020 |
Impaired "Glycine"-mia in Type 2 Diabetes and Potential Mechanisms Contributing to Glucose Homeostasis.
Topics: Animals; Bariatric Surgery; Diabetes Mellitus, Type 2; Glucose; Glycine; Homeostasis; Humans; Insuli | 2017 |
Insulin resistance and glycine metabolism in humans.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Insulin Resistance; Models, Biological | 2018 |
Linking Metabolic Disease With the PGC-1α Gly482Ser Polymorphism.
Topics: Amino Acid Substitution; Diabetes Mellitus, Type 2; Genetic Linkage; Genetic Predisposition to Disea | 2018 |
Assessing the causal association of glycine with risk of cardio-metabolic diseases.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Genetic Loci; Genetic Predisposition to Disease; Genome | 2019 |
Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases.
Topics: Biological Availability; Diabetes Mellitus, Type 2; Diet; Gastrointestinal Microbiome; Glycine; Huma | 2019 |
Association of the ADIPOQ T45G polymorphism with insulin resistance and blood glucose: a meta-analysis.
Topics: Adiponectin; Amino Acid Substitution; Blood Glucose; Case-Control Studies; Cross-Sectional Studies; | 2014 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractur | 2014 |
Toll-like receptor 4 gene Asp299Gly and Thr399Ile polymorphisms in type 2 diabetes mellitus: a meta-analysis of 15,059 subjects.
Topics: Amino Acid Substitution; Aspartic Acid; Case-Control Studies; Diabetes Mellitus, Type 2; Genetic Pre | 2015 |
Beneficial Effects of the Amino Acid Glycine.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 2; Glycine; Humans; Insulin Resistance; Kidney; Liver | 2017 |
Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies.
Topics: Amino Acid Substitution; Arginine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Genetic Carrier Scr | 2003 |
[S20G mutation of amylin gene--amyloid diabetes due to S20G amylin gene mutation].
Topics: Amino Acid Sequence; Amino Acid Substitution; Amyloid; Animals; Diabetes Mellitus, Type 2; Genetic P | 2005 |
[HNF-1alpha G319S mutation in Oji-Cree type 2 diabetes].
Topics: Amino Acid Substitution; Canada; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Genetic Predisposi | 2005 |
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Th | 2005 |
Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Glycine; Heat-Shock Proteins; Hu | 2006 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glyc | 2006 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glyci | 2006 |
Muraglitazar and the FDA: what constitutes drug safety?
Topics: Animals; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Human | 2006 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, B | 2006 |
15 trials available for glycine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Glycated Proteins, Glycine, Acetate, and Monounsaturated Fatty Acids May Act as New Biomarkers to Predict the Progression of Type 2 Diabetes: Secondary Analyses of a Randomized Controlled Trial.
Topics: Acetates; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturate | 2022 |
Glycated Proteins, Glycine, Acetate, and Monounsaturated Fatty Acids May Act as New Biomarkers to Predict the Progression of Type 2 Diabetes: Secondary Analyses of a Randomized Controlled Trial.
Topics: Acetates; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturate | 2022 |
Glycated Proteins, Glycine, Acetate, and Monounsaturated Fatty Acids May Act as New Biomarkers to Predict the Progression of Type 2 Diabetes: Secondary Analyses of a Randomized Controlled Trial.
Topics: Acetates; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturate | 2022 |
Glycated Proteins, Glycine, Acetate, and Monounsaturated Fatty Acids May Act as New Biomarkers to Predict the Progression of Type 2 Diabetes: Secondary Analyses of a Randomized Controlled Trial.
Topics: Acetates; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturate | 2022 |
The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Topics: Adiponectin; AMP-Activated Protein Kinases; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty | 2015 |
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2008 |
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Diabetes Mellitus, Type 2; Edema; Endothelin-1; Female; Gene Expression Regulation; Glycine | 2008 |
Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes.
Topics: Aged; Cytokines; Diabetes Mellitus, Type 2; Female; Glycine; Humans; Hypoglycemic Agents; Inflammati | 2008 |
Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therap | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; D | 2009 |
Metabolic effects of muraglitazar in type 2 diabetic subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; | 2011 |
Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine.
Topics: Adult; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Glucagon; Glucagon-Secreting Cell | 2013 |
Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome.
Topics: Analysis of Variance; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genetic Variation; | 2005 |
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycate | 2005 |
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyc | 2006 |
Effect of glycine on hemoglobin glycation in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycine; Hum | 1999 |
Effect of glycine on insulin secretion and action in healthy first-degree relatives of type 2 diabetes mellitus patients.
Topics: Administration, Oral; Adolescent; Adult; Diabetes Mellitus, Type 2; Family Health; Female; Glycine; | 2001 |
Intestinal glucose and amino acid absorption in healthy volunteers and noninsulin-dependent diabetic subjects.
Topics: Adult; Amino Acids; Diabetes Mellitus, Type 2; Female; Glucose; Glycine; Humans; Intestinal Absorpti | 1989 |
90 other studies available for glycine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
SIT1 transporter as a potential novel target in treatment of COVID-19.
Topics: COVID-19; Diabetes Mellitus, Type 2; Glycine; Humans; Membrane Transport Proteins | 2021 |
NMR-Based Metabolomic Analysis for the Effects of Trimethylamine N-Oxide Treatment on C2C12 Myoblasts under Oxidative Stress.
Topics: Alanine; Catalase; Diabetes Mellitus, Type 2; Glycine; Histidine; Humans; Hydrogen Peroxide; Isoleuc | 2022 |
[Electroacupuncture preconditioning alleviates renal injury and oxidative stress through Sirt3/MnSOD pathway in type 2 diabetic rats].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acupuncture Points; Animals; Catalase; Diabetes Mellitus, Experimental; | 2022 |
Isotope-edited vibrational circular dichroism study reveals a flexible N-terminal structure of islet amyloid peptide (NFGAIL) in amyloid fibril form: A site-specific local structural analysis.
Topics: Amyloid; Diabetes Mellitus, Type 2; Glycine; Humans; Isotopes; Peptides; Phenylalanine | 2022 |
Metabolomics profiles associated with HbA1c levels in patients with type 2 diabetes.
Topics: Aged; Amino Acids; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated H | 2019 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; | 2020 |
An association between glycine and insulin levels is observed in patients with pulmonary tuberculosis and type 2 diabetes.
Topics: Adult; Biomarkers; Blood Glucose; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, | 2020 |
Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease.
Topics: Aged; Carbamoyl-Phosphate Synthase (Ammonia); Case-Control Studies; Diabetes Mellitus, Type 2; Femal | 2020 |
Obesity increases hepatic glycine dehydrogenase and aminomethyltransferase expression while dietary glycine supplementation reduces white adipose tissue in Zucker diabetic fatty rats.
Topics: Adipose Tissue, White; Alanine; Aminomethyltransferase; Animals; Appetite Regulation; Body Weight; D | 2020 |
The use of combined high-fructose diet and glyphosate to model rats type 2 diabetes symptomatology.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Fructose; Glycine; | 2021 |
Mendelian Randomization Study on Amino Acid Metabolism Suggests Tyrosine as Causal Trait for Type 2 Diabetes.
Topics: Adult; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Case-Control Studies; Diabetes Mellitus, | 2020 |
A cross-platform approach identifies genetic regulators of human metabolism and health.
Topics: Diabetes Mellitus, Type 2; Eye Diseases; Gene Frequency; Genetic Loci; Genetic Pleiotropy; Genome, H | 2021 |
Hormonal regulation of glycine decarboxylase and its relationship to oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastrointestinal Agents; Gene E | 2021 |
Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Computational Biology; Diabetes Mellitus, Type 2; Fema | 2018 |
Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glu | 2014 |
Impaired gallbladder motility in adults with newly detected type 2 diabetes and lack of reversibility after achieving euglycemia.
Topics: Adult; Aniline Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gallbladder; Gallbladder | 2015 |
Alterations of urinary metabolite profile in model diabetic nephropathy.
Topics: Aconitic Acid; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2015 |
Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Design; Female; Glycine; Hypoglycemic Agents | 2015 |
Lack of association between the insulin receptor substrates-1 Gly972Arg polymorphism and type-2 diabetes mellitus among Saudis from Eastern Saudi Arabia.
Topics: Adult; Aged; Arginine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycine; Humans; Ins | 2015 |
A Glycine-Insulin Autocrine Feedback Loop Enhances Insulin Secretion From Human β-Cells and Is Impaired in Type 2 Diabetes.
Topics: Animals; Calcium; Diabetes Mellitus, Type 2; Electrophysiology; Glycine; Humans; Immunohistochemistr | 2016 |
PGC-1alpha Gly482Ser polymorphism is associated with the plasma adiponectin level in type 2 diabetic men.
Topics: Adiponectin; Aged; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glycine; Heat-Shock Proteins; | 2008 |
K469E polymorphism of the intracellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2 diabetes.
Topics: Aged; Alanine; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Re | 2008 |
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Carboxylic Acids; Chemistry, Pharmaceutical; Crystallography | 2009 |
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Chemistry, Pharmaceutical; Crystallography, X-Ray; Cytochrom | 2009 |
The G1057D polymorphism of IRS-2 gene is not associated with type 2 diabetes and obese patients among ethnic groups in Tunisian population.
Topics: Aspartic Acid; Black People; Diabetes Mellitus, Type 2; Ethnicity; Female; Genetic Predisposition to | 2009 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hy | 2009 |
Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in Chinese population.
Topics: Adult; Aged; Amino Acid Substitution; Case-Control Studies; China; Diabetes Mellitus, Type 2; Diabet | 2009 |
Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study.
Topics: Aged; Arginine; Body Mass Index; Diabetes Mellitus, Type 2; Gene Frequency; Genetic Predisposition t | 2010 |
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycine; Hypoglycem | 2010 |
Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine.
Topics: Cysteine; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Glutathione; Glycine; Humans; Male | 2011 |
[Effects of glycine on auditory evoked potentials among diabetic patients with auditory pathway neuropathy].
Topics: Audiometry; Auditory Pathways; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Evoked Potentials, | 2010 |
Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats.
Topics: Adiponectin; Animals; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Dietary Fats; Dyslipidemias; Fat | 2012 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; | 2012 |
A novel missense mutation in the signal peptide of the human POMC gene: a possible additional link between early-onset type 2 diabetes and obesity.
Topics: Animals; Arginine; Cell Line, Tumor; Coronary Disease; Diabetes Mellitus, Type 2; Female; Genetic Lo | 2012 |
Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Glycine; Hexoses; Humans; Insulin; Insulin Res | 2013 |
Association of the G-250A promoter polymorphism in the hepatic lipase gene with the risk of type 2 diabetes mellitus.
Topics: Adult; Aged; Alanine; Amino Acid Substitution; Asian People; Case-Control Studies; Diabetes Mellitus | 2013 |
Arg399Gln polymorphism of X-ray repair cross-complementing group 1 gene is associated with angiographically documented coronary artery disease in South Indian type 2 diabetic patients.
Topics: Arginine; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; DNA-Binding Prot | 2013 |
Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes.
Topics: Adult; Betaine; Diabetes Mellitus, Type 2; Female; Glycine; Humans; Insulin Resistance; Male; Middle | 2013 |
Identification of three new mutations of the HNF-1 alpha gene in Japanese MODY families.
Topics: Adult; Amino Acid Substitution; Animals; COS Cells; Cysteine; Diabetes Mellitus, Type 2; DNA-Binding | 2002 |
Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Aspartic Acid; Cohort Studies; Diabetes Mellitus, Type 2; Fibroblasts; Gene Fr | 2003 |
A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians.
Topics: Adipocytes; Adipose Tissue; Adult; Alleles; Blood Glucose; Body Composition; Body Mass Index; Cell S | 2003 |
Serum extracellular superoxide dismutase in patients with type 2 diabetes: relationship to the development of micro- and macrovascular complications.
Topics: Amino Acid Substitution; Arginine; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angi | 2003 |
S20G mutation of the amylin gene is associated with a lower body mass index in Korean type 2 diabetic patients.
Topics: Age of Onset; Amino Acid Substitution; Amyloid; Asian People; Body Mass Index; Diabetes Mellitus, Ty | 2003 |
Metabolic effects of the Gly1057Asp polymorphism in IRS-2 and interactions with obesity.
Topics: Adult; Amino Acid Substitution; Animals; Arizona; Aspartic Acid; Base Sequence; Body Composition; Co | 2003 |
Genotype Gly/Gly of the Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients.
Topics: Aged; Arginine; Diabetes Mellitus, Type 2; Fasting; Female; Genotype; Glucose; Glucose Tolerance Tes | 2004 |
Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes.
Topics: Amino Acid Substitution; Aspartic Acid; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabet | 2004 |
The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes.
Topics: Adipose Tissue; Adult; Alanine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genotype; G | 2004 |
A Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genetic Predisposition to D | 2004 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Huma | 2005 |
Molecular scanning of the betacellulin gene for mutations in type 2 diabetic patients.
Topics: Aged; Amino Acid Substitution; Base Sequence; Betacellulin; Cysteine; Cytosine; Diabetes Mellitus, T | 2005 |
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Topics: Adamantane; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; | 2005 |
Molecule of the month. Muraglitazar.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Oxazoles; PPAR alpha; PPAR gamma | 2005 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Piogl | 2005 |
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellit | 2005 |
Selling safety--lessons from muraglitazar.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Age | 2005 |
One pill, two conditions.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypercholestero | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycin | 2006 |
The Gly146Ala variation in human SF-1 gene: its association with insulin resistance and type 2 diabetes in Chinese.
Topics: Alanine; Chi-Square Distribution; China; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genetic | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic | 2006 |
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycine; Humans; Hypogl | 2006 |
Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Topics: Amino Acid Substitution; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose Intolerance | 2006 |
[Association of Gly82Ser polymorphism of receptor for advanced glycation end products gene in a type 2 diabetic Chinese population].
Topics: Aged; Amino Acid Substitution; Asian People; China; Diabetes Mellitus, Type 2; Female; Gene Frequenc | 2007 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; | 2006 |
Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes.
Topics: Adult; Basal Metabolism; Body Weight; Diabetes Mellitus, Type 2; Female; Glycine; Humans; Kinetics; | 2008 |
Polymorphism of the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans.
Topics: Adult; Aged; Alleles; Black People; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2007 |
A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the association with diabetes mellitus.
Topics: Adolescent; Adult; Age of Onset; Aged; Diabetes Mellitus, Type 2; France; Genetic Linkage; Glycine; | 1995 |
Isolation and characterization of the human muscle glycogen synthase gene.
Topics: Adult; Amino Acid Sequence; Animals; Base Sequence; Deoxyribonucleases, Type II Site-Specific; Diabe | 1995 |
Clinical characteristics of subjects with a missense mutation in glucokinase.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Arginine; Blood Glucose; Blood Pressure; C- | 1995 |
Insulin receptor substrate-1 gene mutations in NIDDM; implications for the study of polygenic disease.
Topics: Adult; Aged; Alanine; Arginine; Base Sequence; Case-Control Studies; Codon; Deoxyribonucleases, Type | 1995 |
Molecular scanning of the glycogen synthase and insulin receptor substrate-1 genes in Japanese subjects with non-insulin-dependent diabetes mellitus.
Topics: Alanine; Alleles; Amino Acid Sequence; Arginine; Base Sequence; Blood Glucose; Diabetes Mellitus, Ty | 1994 |
The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Exons; G | 1996 |
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies.
Topics: Arginine; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Diabetes Mellitus, Type 2; DNA; E | 1996 |
[The motility of the biliary tract studied with 99mTc-Br-IDA in patients with type-2 diabetes mellitus].
Topics: Aged; Aniline Compounds; Biliary Tract; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fasting; F | 1995 |
Lack of association between the Gly40Ser polymorphism in the glucagon receptor gene and NIDDM in Finland.
Topics: Alleles; Amino Acid Sequence; Base Sequence; Diabetes Mellitus, Type 2; DNA Primers; Finland; France | 1995 |
Absence of the Gly40-Ser mutation in the glucagon receptor among diabetic patients in the Netherlands.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Frequency; Glycine; | 1995 |
Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus.
Topics: Amino Acid Sequence; Base Sequence; Diabetes Mellitus, Type 2; DNA Primers; Glycine; Humans; Insulin | 1996 |
No association between the Gly971Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population.
Topics: Adult; Amino Acid Sequence; Arginine; Base Sequence; Child; Diabetes Mellitus, Type 2; DNA Primers; | 1996 |
Gly40Ser substitution in the glucagon receptor is rarely involved in the pathogenesis of NIDDM in Japanese patients.
Topics: Base Sequence; Codon; Diabetes Mellitus, Type 2; DNA Primers; Female; Glycine; Humans; Japan; Male; | 1996 |
Absence of association between the Gly40-->Ser mutation in the human glucagon receptor and Japanese patients with non-insulin-dependent diabetes mellitus or impaired glucose tolerance.
Topics: Adult; Aged; Asian People; Codon; Diabetes Mellitus, Type 2; Exons; Female; Glucose Intolerance; Gly | 1996 |
Effect of exogenous insulin on protein metabolism with differing nonprotein energy intakes in Type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Proteins; Energy Intake; | 1998 |
Hemoglobin Rambam (beta69[E13]Gly-->Asp), a pitfall in the assessment of diabetic control: characterization by electrospray mass spectrometry and HPLC.
Topics: Amino Acid Sequence; Aspartic Acid; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; | 1998 |
Missense mutation Gly574Ser in the transcription factor HNF-1alpha is a marker of atypical diabetes mellitus in African-American children.
Topics: Adult; Amino Acid Substitution; Black People; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 1999 |
RAGE Gly82Ser polymorphism in diabetic microangiopathy.
Topics: Amino Acid Substitution; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gene Frequency; Genotype; | 1999 |
Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes.
Topics: Adult; Amino Acid Substitution; Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Family; Female; | 1999 |
Analysis of the Gly40Ser polymorphism in the glucagon receptor gene in a German non-insulin-dependent diabetes mellitus population.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Europe; Gene Frequency; Germany; Glycine; Humans; Japan; Mid | 1999 |
Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes.
Topics: Amino Acid Substitution; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2000 |
S20G mutation of the amylin gene in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Amyloid; Asian People; Blood Glucose; Diabe | 2000 |
Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes.
Topics: Aged; Analysis of Variance; Arginine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genet | 2001 |
Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading.
Topics: 17-Ketosteroids; Amidinotransferases; Animals; Chronic Disease; Citrulline; Creatine; Diabetes Melli | 1992 |